CORONAVIRUS

Merck says experimental pill cuts worst effects of COVID-19

Oct 1, 2021, 5:36 AM
FILE PHOTO (Photo by Erik S. Lesser/Getty Images)...
FILE PHOTO (Photo by Erik S. Lesser/Getty Images)
(Photo by Erik S. Lesser/Getty Images)

WASHINGTON (AP) — Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.

If cleared, Merck’s drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.

Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease.

Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck. The results were released by the company and have not been peer reviewed. Merck said it plans to present them at a future medical meeting.

An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. Company executives said they are in discussions with the Food and Drug Administration and plan submit the data for review in coming days.

“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice president of Merck research. “When you see a 50% reduction in hospitalization or death that’s a substantial clinical impact.”

Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.

Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to given by IV or injection at hospitals or medical clinics, and supplies have been stretched by the latest surge of the delta variant.

Health experts including the top U.S. infectious disease expert Dr. Anthony Fauci have long called for a convenient pill that patients could take when COVID-19 symptoms first appear, much the way the decades-old flu medication Tamiflu helps fight influenza. Such medications are seen as key to controlling future waves of infection and reducing the impact of the pandemic.

Merck’s pill works by interfering with an enzyme the coronavirus uses to copy its genetic code and reproduce itself. It has shown similar activity against other viruses.

The U.S. government has committed to purchase 1.7 million doses of the drug if it is authorized by the FDA. Merck has said it can produce 10 million doses by the end of the year and has contracts with governments worldwide. The company has not announced prices.

Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.

Merck had planned to enroll more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe and Africa. Executives estimated about 10% of patients studied were from the U.S.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

KSL 5 TV Live

Top Stories

Coronavirus

(KSL-TV)...
Katija Stjepovic

Utah arts and cultural jobs are surging after COVID pandemic

The COVID-19 pandemic pulled the curtains on most of Utah's arts and cultural jobs, but after nearly three years, they are reemerging. 
1 day ago
...
Ashley Moser

Flu, COVID and RSV all trending down for the first time in months, says CDC

Major respiratory illnesses are all trending down for the first time since September, according to the CDC.
15 days ago
FILE PHOTO (Photo by Matthew Hatcher/Getty Images)...
Josh Ellis

Utah doctor, others charged with running COVID vaccine scheme, issuing fake records and giving fake shots

A Utah plastic surgeon, his medical corporation and three others have been charged after prosecutors say they issued fake COVID-19 vaccination record cards and injected minors with saline shots.
21 days ago
Dr. Angela Dunn, executive director of Salt Lake County Health Department, left, discusses schoolch...
Michael Houck

Salt Lake County ends its COVID-19 emergency status

After nearly three years, the Salt Lake County Health Department ended its COVID emergency status Tuesday. 
29 days ago
FILE: People line up in their cars as members of the Utah National Guard give COVID-19 swab tests a...
Eliza Pace

Gov. Cox, along with 24 other governors, call on President Biden to end Federal Public Health Emergency

Gov. Spencer Cox signed a letter with 24 other governors calling on President Joe Biden to end the federal public health emergency over the COVID-19 pandemic.
2 months ago
U.S. President Joe Biden welcomes guests to the East Room of the White House on December 14, 2022 i...
ZEKE MILLER, AP White House Correspondent

White House reveals winter COVID-19 plans, more free tests

The Biden administration is again making some free COVID-19 tests available to all U.S. households as it unveils its contingency plans for potential coronavirus surges this winter.
2 months ago

Sponsored Articles

vintage photo of lighting showroom featuring chandeliers, lamps, wall lights and mirrors...
Lighting Design

History of Lighting Design | Over 25 Years of Providing Utah With the Latest Trends and Styles

Read about the history of Lighting Design, a family-owned and operated business that paved the way for the lighting industry in Utah.
Fiber Optical cables connected to an optic ports and Network cables connected to ethernet ports...
Brian Huston, CE and Anthony Perkins, BICSI

Why Every Business Needs a Structured Cabling System

A structured cabling system benefits businesses by giving you faster processing speeds and making your network more efficient and reliable.
notebook with password notes highlighted...
PC Laptops

How to Create Strong Passwords You Can Actually Remember

Learn how you can create strong passwords that are actually easy to remember! In a short time you can create new ones in seconds.
house with for rent sign posted...
Chase Harrington, president and COO of Entrata

Top 5 Reasons You May Want to Consider Apartment Life Over Owning a Home

There are many benefits of renting that can be overshadowed by the allure of buying a home. Here are five reasons why renting might be right for you.
Festive kitchen in Christmas decorations. Christmas dining room....
Lighting Design

6 Holiday Decor Trends to Try in 2022

We've rounded out the top 6 holiday decor trends for 2022 so you can be ahead of the game before you start shopping. 
Happy diverse college or university students are having fun on their graduation day...
BYU MBA at the Marriott School of Business

How to Choose What MBA Program is Right for You: Take this Quiz Before You Apply!

Wondering what MBA program is right for you? Take this quiz before you apply to see if it will help you meet your goals.
Merck says experimental pill cuts worst effects of COVID-19